StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
14
This year
2
Publishing Date
2024 - 03 - 19
1
2024 - 02 - 15
1
2023 - 03 - 07
1
2022 - 11 - 14
1
2022 - 10 - 17
1
2022 - 07 - 26
2
2022 - 06 - 13
1
2022 - 04 - 26
1
2022 - 03 - 28
1
2022 - 01 - 24
2
2021 - 05 - 20
1
2021 - 03 - 18
1
Sector
Health technology
14
Manufacturing
1
Tags
Active
3
Agreement
7
Alliances
5
Als
12
Application
7
Approval
7
Biotech-beach
14
Cardiovascular
4
Clinical-trials-phase-ii
5
Clinical-trials-phase-iii
8
Commercial
3
Commercialization
5
Companies
5
Conference
14
Covid
3
Covid-19
5
Designation
8
Disease
14
Drug
14
Earnings
7
Eplontersen
16
Events
13
Fda
13
Financial
13
Financial results
10
Genetic
11
Genetown
4
Global
6
Grant
6
Granted
6
Grants
4
Growth
10
Hereditary angioedema
6
Market
22
Meeting
5
N/a
142
Pharmaceutical
4
Phase 2
7
Phase 2b
5
Phase 3
9
Positive
21
Potential
9
Presentation
6
Program
9
Rare
7
Report
7
Research
17
Results
43
Review
4
Spinraza
5
Study
19
Symposium
4
Technology
4
Therapeutics
5
Therapy
10
Topline
8
Treatment
19
Trial
7
Update
4
Year
4
Entities
Ascendis pharma a/s
1
Astellas pharma inc
1
Biogen inc.
3
Eli lilly and company
1
Ionis pharmaceuticals, inc.
14
Johnson & johnson
1
Novartis ag
1
Pfizer, inc.
1
Teva pharmaceutical industries ltd
1
Symbols
ABBV
75
ABT
65
ALGS
17
ALNY
11
ALPMF
27
ALPMY
27
AMGN
54
ARDX
11
ARQT
11
ARVL
11
AZN
70
AZNCF
48
BAX
15
BDX
34
BHC
22
BIIB
28
BIO
12
BMY
63
BSX
13
CERT
11
CRL
13
DHR
14
ENDP
13
ENVB
12
EVOTF
20
FNCTF
27
GILD
25
GLAXF
77
GLPG
12
GSK
110
HOTH
12
IMAB
11
INBS
19
INCY
33
IONS
14
JAGX
33
JNJ
224
LEXX
11
LH
14
LLY
105
LTRN
33
MDT
24
MNKD
12
NNVC
21
NVO
18
NVS
116
NVSEF
86
PFE
54
PRGO
13
SNY
243
SNYNF
176
SRNE
11
STRO
12
TAK
30
TEVJF
44
TMO
48
TNXP
12
VTRS
15
WST
14
ZLAB
11
Exchanges
Nasdaq
14
Nyse
1
Crawled Date
2024 - 03 - 19
1
2024 - 02 - 15
1
2023 - 03 - 07
1
2022 - 11 - 14
1
2022 - 10 - 17
1
2022 - 07 - 26
2
2022 - 06 - 13
1
2022 - 04 - 26
1
2022 - 03 - 28
1
2022 - 01 - 24
2
2021 - 05 - 20
1
2021 - 03 - 18
1
Crawled Time
06:00
1
12:00
4
12:20
2
12:30
1
13:00
3
14:00
1
16:03
2
Source
www.biospace.com
7
www.fda.gov
2
www.globenewswire.com
2
www.prnewswire.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Drug
symbols :
Ions
save search
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
Published:
2024-03-19
(Crawled : 12:30)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
-0.45%
|
O:
-0.33%
H:
1.89%
C:
0.64%
drug
health
genetic
als
review
treatment
canada
submission
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Published:
2024-02-15
(Crawled : 13:00)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
-14.73%
|
O:
-1.53%
H:
3.16%
C:
-6.29%
fda
drug
designation
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Published:
2023-03-07
(Crawled : 12:20)
- prnewswire.com
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
15.42%
|
O:
0.66%
H:
0.0%
C:
-2.27%
treatment
fda
drug
application
eplontersen
Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China Akeso, Biopharma announced that the Center for Drug Evalua...
Published:
2022-11-14
(Crawled : 06:00)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
-3.26%
|
O:
0.35%
H:
4.08%
C:
1.47%
ASND
|
$145.17
2.16%
2.11%
220K
|
Health Technology
|
9.74%
|
O:
-13.42%
H:
4.11%
C:
-3.5%
ak112
biopharma
designation
drug
granted
china
therapy
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Published:
2022-10-17
(Crawled : 12:00)
- globenewswire.com
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
-9.75%
|
O:
0.97%
H:
1.62%
C:
-0.62%
BIIB
|
$193.18
-0.48%
-0.48%
1.4M
|
Health Technology
|
-27.0%
|
O:
0.54%
H:
2.99%
C:
1.32%
drug
extension
application
review
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Published:
2022-07-26
(Crawled : 12:00)
- prnewswire.com
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
9.19%
|
O:
1.96%
H:
0.2%
C:
-2.61%
fda
drug
genetic
als
application
grants
review
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Published:
2022-07-26
(Crawled : 12:00)
- globenewswire.com
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
9.19%
|
O:
1.96%
H:
0.2%
C:
-2.61%
BIIB
|
$193.18
-0.48%
-0.48%
1.4M
|
Health Technology
|
-6.93%
|
O:
-0.42%
H:
3.54%
C:
2.01%
fda
drug
genetic
als
application
grants
review
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
Published:
2022-06-13
(Crawled : 12:00)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
22.41%
|
O:
-0.29%
H:
0.13%
C:
-1.7%
treatment
fda
rare
drug
disease
designation
Global Genitourinary Drugs Market Research Report to 2027 - Increasing Prevalence of Genitourinary Disorders is Driving Growth
Published:
2022-04-26
(Crawled : 14:00)
- prnewswire.com
ALPMF
|
News
|
$9.75
43.47%
200
|
Health Technology
|
-38.35%
|
O:
2.56%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.53
-1.11%
690K
|
Manufacturing
|
-40.2%
|
O:
0.13%
H:
0.06%
C:
-0.69%
PFE
|
News
4
|
$26.32
0.23%
0.0%
24M
|
Health Technology
|
-44.95%
|
O:
3.08%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
10.04%
|
O:
0.47%
H:
0.83%
C:
-1.44%
JNJ
|
News
|
$149.56
0.3%
0.0%
9.1M
|
Health Technology
|
-18.04%
|
O:
2.0%
H:
0.0%
C:
0.0%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
159.13%
|
O:
0.34%
H:
1.41%
C:
-1.17%
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
-1.18%
|
O:
-0.12%
H:
0.07%
C:
-5.13%
research
report
growth
market
drug
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Published:
2022-03-28
(Crawled : 12:20)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
14.1%
|
O:
-1.12%
H:
1.96%
C:
-1.05%
BIIB
|
$193.18
-0.48%
-0.48%
1.4M
|
Health Technology
|
-8.43%
|
O:
-0.42%
H:
1.04%
C:
0.76%
drug
results
topline
sclerosis
phase 1
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
Published:
2022-01-24
(Crawled : 13:00)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
40.92%
|
O:
-1.45%
H:
7.89%
C:
7.31%
fda
drug
orphan drug
designation
eplontersen
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
Published:
2022-01-24
(Crawled : 13:00)
- biospace.com/
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
40.92%
|
O:
-1.45%
H:
7.89%
C:
7.31%
drug
granted
orphan drug
grant
designation
eplontersen
Drug Trial Snapshot: TEGSEDI
Published:
2021-05-20
(Crawled : 16:03)
- fda.gov
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
18.33%
|
O:
0.14%
H:
5.31%
C:
3.25%
trial
drug
Drug Trial Snapshot: TEGSEDI
Published:
2021-03-18
(Crawled : 16:03)
- fda.gov
IONS
|
$41.85
1.9%
1.86%
630K
|
Health Technology
|
-21.57%
|
O:
-0.66%
H:
2.34%
C:
-0.38%
drug
trial
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.